Mayzent
Mayzent
Mayzent
Kymriah
Kymriah
Myfortic
Myfortic
Lucentis
Lucentis
Lucentis
Lucentis
Gilenya
Gilenya
Gilenya
Exjade
Exjade
Exjade
Exelon
Beovu
Beovu
FOR UNRESECTABLE OR METASTATIC MELANOMA
FOR STAGE Ill MELANOMA
ATECTURA® BREEZHALER® Placebos
ENERZAIR® BREEZHALER® Placebos

IE447621 | May 2024

×

Ask Speakers

×

Medical Information Request

Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing [email protected] or by calling (01) 2080 612.